Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Other Working Capital Changes (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Other Working Capital Changes for 11 consecutive years, with -$126000.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 59.74% to -$126000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$483000.0 through Dec 2025, down 122.58% year-over-year, with the annual reading at -$483000.0 for FY2025, 122.58% down from the prior year.
  • Other Working Capital Changes hit -$126000.0 in Q4 2025 for Aptevo Therapeutics, down from -$83000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.4 million in Q3 2021 to a low of -$1.5 million in Q2 2023.
  • Historically, Other Working Capital Changes has averaged -$82200.0 across 5 years, with a median of -$211000.0 in 2022.
  • Biggest five-year swings in Other Working Capital Changes: skyrocketed 384.12% in 2023 and later plummeted 314.38% in 2024.
  • Year by year, Other Working Capital Changes stood at -$475000.0 in 2021, then skyrocketed by 157.89% to $275000.0 in 2022, then plummeted by 46.91% to $146000.0 in 2023, then crashed by 314.38% to -$313000.0 in 2024, then soared by 59.74% to -$126000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for APVO at -$126000.0 in Q4 2025, -$83000.0 in Q3 2025, and $203000.0 in Q2 2025.